Definitive Contract HHSN261200533000C
Award Date 8/15/05
Potential Completion Date 4/30/13
Potential Value $20M
Federal Agency
Ultimate Awardee
NAICS Category
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Oklahoma City, OK 73117, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award is for a delivery order under the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle. The contract was awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Oklahoma (OU) Univ Of Oklahoma Health Sciences Center Division. The contract is for "OTHER FUNCTIONS - PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS - CONTRACT ORIENTATION...
- This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The contract is part of the Preclinical Agent Development Assays 2012-2016 indefinite delivery, indefinite quantity (IDIQ) vehicle. It is for "OTHER FUNCTIONS - IN VITRO AND IN VIVO AGENT DEVELOPMENT ASSAYS" services with a ceiling value of $1,899.49....
- This is a $819,519.17 cost-reimbursement delivery order awarded by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The order is placed under the Preclinical Agent Development Assays 2012-2016 contract vehicle and supports the development of inhibitors for MPGES-1 and 5-LOX proteins for use as colon cancer chemopreventive agents. This work is part of the agency's...
- This is a firm fixed-price delivery order contract awarded by the National Cancer Institute, part of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ of Oklahoma Health Sciences Center Division. The $628,343 contract is for research and development related to the Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. This work is not set aside for small businesses. The University of Oklahoma, acting...
- <p>This federal contract award was made by the National Cancer Institute, a civilian agency, to the University of Oklahoma Inc. for the FINAL_CLOSE_PROCESS effort. The contract is a definitive, cost-no-fee contract with a ceiling value of $17,883,428.00. The contract does not have a set-aside designation and has an ultimate completion date of January 30, 2011. The award date was January 15, 2003. This contract award is not associated with a larger vehicle.</p>
- The federal contract award, with ID 75N91019D00020|75N91020F00003, was granted by the National Cancer Institute to the University of Oklahoma Health Sciences Center Division, a public research university in Oklahoma City, Oklahoma. The contract is for the "PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS" with a task order titled "URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN) WHEN...
- This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Oklahoma Health Sciences Center Division. The contract is part of the NCI's "PREVENT Cancer Program (PREVENT)" and covers a "CONTRACT ORIENTATION AND KICK-OFF MEETING" with a period of performance from September 22, 2015 to December 31, 2015. The contract has a ceiling value of $4,217.44 and is a Delivery Order...
- This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU) for "TARGETING CCK2R FOR PANCREATIC CANCER PREVENTION". The $474,197.46 contract is part of the NCI's Preclinical Agent Development Assays 2012-2016 program, which focuses on preclinical in vitro and in vivo agent development assays. The award does not have a set-aside designation. As...
- The National Cancer Institute issued a delivery order to the University of Oklahoma Health Sciences Center on September 15, 2021, under the PREVENT Preclinical Drug Development Program IDIQ for further evaluation of AMHR2-ED antigens for epithelial ovarian carcinoma. The order carries a $1.02 million ceiling with a firm fixed price structure and an ultimate completion date of September 14, 2026. Place of performance is Oklahoma City, OK. SCI reporting shows government-invoiced labor declining...
- The University of Oklahoma Health Sciences Center (OUHSC) was awarded a $909,993.85 firm fixed-price delivery order by the National Cancer Institute on September 21, 2020, for the evaluation of two different classes of compounds—STAT3 inhibitors and selective estrogen receptor modulators (SERMs)—for the prevention of urinary bladder cancer. This delivery order is issued under the PREVENT Cancer Preclinical Drug Development Program, an expansive National Cancer Institute Indefinite...